ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO884

Parathyroidectomy (PTX), KDOQI Targets, PTH Lowering Therapies, and Mortality in a Cohort of Italian Dialysis (D) Patients: A Multicenter Observational Study

Session Information

  • Mineral Disease: CKD-Bone
    November 04, 2017 | Location: Hall H, Morial Convention Center
    Abstract Time: 10:00 AM - 10:00 AM

Category: Mineral Disease

  • 1203 Mineral Disease: CKD-Bone

Author

  • Mazzaferro, Sandro, Sapienza University of Rome, Rome, Italy

Group or Team Name

  • On behalf of Italian Study Group of Mineral Metabolism
Background

PTX might improve survival by improving biochemical control.

Methods

We prospectively collected data of 528 prevalent PTX cases (age: 57.63±12.52 y.o; D time: 14.63±8.37 y; M/F: 44/56%) from 149 D units in Italy, out of 12515 patients on D (=4,2%) and evaluated KDOQI targets, therapies and survival. Control cases (n=418, nested case-control selection) were balanced for sex (45/55%) but not age (60.30±14.36 y.o, p<.01) or D duration (11.2±7.3 y; p<.001).

Results

PTX cases were at lower KDOQI targets for Ca (50 vs 57 %; p<.05) and PTH (19 vs 37%; p<.001) and received more calcitriol and Ca-based phosphate binders and less calcimimetic than controls. Also PTX cases included in the follow-up were less frequently at target for PTH and were confirmed to receive more calcitriol and Ca-based phosphate binders and less calcimimetic than controls (table 1). Univariate analysis adjusted for D age, showed lower HR of mortality for PTX (0.556, CI:0.387-0.800, p=.002), albumin (0.327; CI:0.249-0.555, p=.000) and hemoglobin (0.672, CI:0.558-0.810, p=.000). Multivariate analysis confirmed PTX (HR 0.679, CI:0.465-0.970, p<.05), age (HR 1.043, CI 1.014-1.055, p<.001) and D duration (HR 1.034, CI 1028-1059, p<.001) as independent predictors of mortality. Albumin inclusion in the model excluded PTX (p=0.065). Indeed, PTX cases had higher albumin levels than controls (3.8±0.4 vs 3.6±0.4; p<.01).

Conclusion

PTX associates with lower risk of mortality regardless of PTH control and despite “more risky” therapy. As a toxin, PTH could negatively affects serum albumin.

Table 1

Funding

  • Commercial Support